DMXAA (Vadimezan) in Cancer Biology: Vascular Disruption ...
2025-09-18
Explore the multifaceted anti-cancer mechanisms of DMXAA (Vadimezan, AS-1404), a vascular disrupting agent and DT-diaphorase inhibitor, with fresh emphasis on endothelial immunity and tumor microenvironment modulation for advanced cancer biology research.